Objectives: To test whether CSF Alzheimer disease biomarkers ], tau, phosphorylated tau at threonine 181 [ptau 181 ], tau/Ab 42 , and ptau 181 /Ab 42 ) predict future decline in noncognitive outcomes among individuals cognitively normal at baseline.
Alzheimer disease (AD) biomarkers can identify "preclinical AD," a state in which AD pathology is present in the brain but the individual has no dementia symptoms or detectable cognitive impairment. It is thought that these biomarkers may become abnormal many years before problems in memory and thinking appear. [1] [2] [3] Biomarkers now are being used in "secondary prevention" trials to identify cognitively normal individuals who are likely to develop symptomatic AD in the future. When dementia symptoms are manifest, substantial neuronal death has already occurred. Therefore, it may be that waiting to administer drugs at the "late" symptomatic stage of AD is responsible for the failure of treatment trials with "disease-modifying" agents.
Earlier work has shown that CSF biomarkers of AD reflecting soluble b-amyloid (Ab), the principal component of amyloid plaques, and tau, the principal component of tangles, predict incident cognitive impairment and dementia. However, "noncognitive" outcomes must also be carefully and systematically assessed in clinical trials of disease-modifying treatments for AD. 4 These outcomes help to more fully reflect the impact of AD treatment on caregiver burden, premature institutionalization, and financial cost. Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
We examined associations between CSF biomarkers and incident cognitive impairment among participants followed up to 14.5 years and tested whether AD biomarker levels predicted future changes in function (independent activities of daily living), weight, behavior, and mood. METHODS Standard protocol approvals, registrations, and patient consents. Study protocols were approved by the Washington University Human Research Protection Office, and written informed consent was obtained from all participants.
Participants. We analyzed annually collected data from participants enrolled in longitudinal studies at the Knight Alzheimer's Disease Research Center. Participants were recruited through word-of-mouth, advertisements, and community events for yearly assessment sessions.
Clinical assessments. The clinician's judgment about the presence of dementia was based on the principle of intraindividual change whereby the individual was used as his or her own control. Based on semistructured interviews with the participant, and separately with a collateral source who knew the participant well, the participant's cognitive and functional performance in each of 6 domains (Memory, Orientation, Judgment & Problem Solving, Community Affairs, Home & Hobbies, and Personal Care) was rated. These ratings were summed to yield the Clinical Dementia Rating (CDR) Sum of Boxes measure. 5 An algorithm was used to calculate the global CDR. 5 A CDR of 0 was taken to indicate normal cognitive functioning, whereas CDRs of 0.5, 1, 2, and 3 indicated very mild, mild, moderate, and severe dementia, respectively. 5 Mini-Mental State Examination (MMSE) 6 scores were also obtained.
Weight was measured in pounds. The collateral source reported instrumental activities of daily living (IADL), which were assessed using the Functional Assessment Questionnaire (FAQ), 7 and behavioral symptoms, using the Neuropsychiatric Inventory Questionnaire (NPI-Q). 8 Depression symptoms were obtained from the participant using the Geriatric Depression Scale (GDS). 9 CSF collection. CSF was obtained via lumbar puncture by trained neurologists using a 22-gauge Sprotte spinal needle to draw 20 to 30 mL of CSF at 8:00 AM following an overnight fast. CSF samples were gently inverted to avoid possible gradient effects and centrifuged at low speed to pellet any cellular debris and frozen at 284°C after aliquoting (0.5 mL) into polypropylene tubes. CSF samples for Ab 42 , tau, and phosphorylated tau at threonine 181 (ptau 181 ) were analyzed using ELISA (INNOTEST; Innogenetics, Ghent, Belgium).
Inclusion criteria. Data from participants who 1) donated CSF
within 1 year of a clinical assessment indicating normal cognition, 2) had at least one additional clinical assessment after the baseline assessment (the assessment closest to the date of CSF donation), 3) and were aged 50 years or older at the time of the baseline assessment were included.
Statistical analyses. We tested whether the CSF biomarkers of Ab 42 , tau, ptau 181 , tau/Ab 42 , and ptau 181 /Ab 42 predicted each of the outcomes of interest. Mixed linear models were used to test whether baseline biomarker values predicted future decline in function (FAQ scores), weight (in pounds), behavior (NPI-Q scores), mood (GDS scores), and CDR Sum of Boxes and MMSE scores. Dichotomous variables reflecting normal and abnormal biomarker values were constructed using the same cutoffs used in previous research (,500 pg/mL for Ab 42 , .440 pg/mL for tau, .78 pg/mL for ptau 181 , .0.94 for tau/Ab 42 , and .0.15 for ptau 181 /Ab 42 ). 10 These analyses included terms adjusting for the effects of age, sex, race (minority vs nonminority), education, and the presence of an APOE e4 allele.
RESULTS Follow-up times ranged from 0.9 year to 14.5 years among the 430 participants meeting inclusion criteria (table 1). Thirty percent of participants (128/427) reported subjective memory or thinking concerns at baseline, answering "Yes" to the question: "Have you had any problems with your thinking or memory?" Values of each biomarker variable were associated with change across time in NPI-Q, GDS, and FAQ scores (table 2), such that abnormal levels of each biomarker were related to greater impairment with time in behavior and mood symptoms, and more difficulties with independent activities of daily living (table 2) . Generally, p values for the ratio variables were smaller than those associated with Ab 42 , tau, and ptau 181 alone. However, biomarker levels were unrelated to weight change with time (table 2) .
Abnormal biomarker values also predicted more rapidly declining performance on the MMSE and CDR Sum of Boxes compared with normal values. Fourteen participants (3.3%) clearly developed dementia (defined as CDR $1 because some investigators consider CDR 0.5 to indicate mild cognitive impairment [MCI] 11 ) over the follow-up period. We repeated the analyses after removing data from these 14 participants from the sample. Generally, results were similar, although most p values reflecting the difference between the normal and abnormal biomarker groups were attenuated (table e-1 on the Neurology ® Web site at www.neurology.org). DISCUSSION Our sample showed cognitive decline with time that was linked to baseline biomarker levels. We also found that abnormal levels of CSF biomarkers predicted decline in the noncognitive outcomes of function, behavior, and mood, but were unrelated to weight changes with time.
Functionality includes the ability to perform IADL such as paying bills, shopping, and preparing meals. Decline in functional activities is an essential diagnostic criterion for AD dementia. Progressive Table 1 Demographics functional decline leads to dependence, which decreases the patient's quality of life, places physical and psychological burdens on the caregiver, and can lead to institutionalization. A previous cross-sectional study found that amyloid burden, imaged using Pittsburgh compound B, correlated with worse performance on IADL among persons with MCI, 12 but there was no cross-sectional relationship between Pittsburgh compound B uptake and IADL among 19 individuals with normal cognition. 12 However, a longitudinal study found that CSF biomarkers of Ab 42 , tau, and ptau 181 predicted future decline on IADL among participants who were cognitively normal at baseline, 13 consistent with our results. An earlier study found that among participants with AD, the CSF biomarker Ab 42 was correlated with the presence of aggressive behaviors. 14 Aggression was not linked to levels of CSF tau or ptau 181 , and none of the biomarkers were correlated with any of the other behaviors studied, including delusions, hallucinations, anxiety, and agitation. 14 Cross-sectional studies show conflicting results regarding mood, with reports that CSF Ab 42 is increased, 15 decreased, 16 and unrelated 14 to depression. However, depression has been found to be associated with greater numbers of amyloid plaques 17, 18 and neurofibrillary tangles at autopsy. 17, 19 To our knowledge, no previous studies have investigated whether abnormal biomarkers in cognitively normal adults predict future behavioral symptoms. We found that depression scores and other behavioral symptoms monitored by the NPI-Q worsen faster among individuals with preclinical AD at baseline as defined by CSF biomarkers.
Weight loss is associated with cognitive impairment, with AD onset, and increases the risk of death. A cross-sectional study found that abnormal CSF levels of Ab 42 and tau were associated with lower body mass index in a sample comprising individuals with and without memory problems (i.e., were cognitively normal, had MCI, or had AD dementia), 20 consistent with a possible link between abnormal AD biomarker levels and weight loss. A literature review did not reveal any prior studies that examined biomarkers as a predictor of future weight loss among cognitively normal individuals. Our nonsignificant results suggest that if such a link exists, the relationship is weaker than the association between CSF biomarkers and the other noncognitive outcomes studied here.
A limitation of the study is that we conducted several statistical tests, and it is possible that some statistical tests were significant by chance. The likelihood of a statistical test being significant by chance decreases with smaller p values. We found that CSF biomarkers among cognitively normal individuals are associated with future decline in some, but not all, noncognitive AD symptoms studied. Future research should test whether the ratios of tau/Ab 42 and ptau 181 /Ab 42 are better predictors of decline in noncognitive outcomes compared with the individual molecular markers alone.
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